OBJECTIVE: To assess the prognostic value of the pro-apoptotic, but also cell growth-inducing molecule soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) in heart failure (HF). METHODS: We assayed sTWEAK levels in 351 patients with advanced HF (non-ischemic: 130, ischemic: 221). During a median follow-up of 4.9 years, 195 patients (56%) died. RESULTS: sTWEAK concentrations were associated with extended survival in patients with non-ischemic (P=0.022), but not with ischemic HF (P=0.82). The inverse association in non-ischemic HF remained significant in a multivariable Cox regression model (P=0.025) with a hazard ratio of 0.40 (95% confidence interval: 0.21-0.77) comparing the third to the first tertile (P=0.007). CONCLUSION: Low sTWEAK levels independently predict mortality in advanced non-ischemic HF. sTWEAK-induced proliferation of cardiomyocytes may explain its impact on suvival. The different prognostic value of sTWEAK in ischemic and non-ischemic HF may point towards distinct pathogenic pathways determining the course of disease.
OBJECTIVE: To assess the prognostic value of the pro-apoptotic, but also cell growth-inducing molecule soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) in heart failure (HF). METHODS: We assayed sTWEAK levels in 351 patients with advanced HF (non-ischemic: 130, ischemic: 221). During a median follow-up of 4.9 years, 195 patients (56%) died. RESULTS: sTWEAK concentrations were associated with extended survival in patients with non-ischemic (P=0.022), but not with ischemic HF (P=0.82). The inverse association in non-ischemic HF remained significant in a multivariable Cox regression model (P=0.025) with a hazard ratio of 0.40 (95% confidence interval: 0.21-0.77) comparing the third to the first tertile (P=0.007). CONCLUSION: Low sTWEAK levels independently predict mortality in advanced non-ischemic HF. sTWEAK-induced proliferation of cardiomyocytes may explain its impact on suvival. The different prognostic value of sTWEAK in ischemic and non-ischemic HF may point towards distinct pathogenic pathways determining the course of disease.
Authors: Mahmut Ilker Yilmaz; Alper Sonmez; Alberto Ortiz; Mutlu Saglam; Selim Kilic; Tayfun Eyileten; Kayser Caglar; Yusuf Oguz; Abdulgaffar Vural; Mustafa Çakar; Jesus Egido; Battal Altun; Mujdat Yenicesu; Luis Miguel Blanco-Colio; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2011-02-17 Impact factor: 8.237
Authors: Arthur Filusch; Thomas Zelniker; Christian Baumgärtner; Sabine Eschricht; Norbert Frey; Hugo A Katus; Emmanuel Chorianopoulos Journal: Clin Res Cardiol Date: 2011-04-11 Impact factor: 5.460
Authors: Bin Yang; Ping Yan; Hui Gong; Lin Zuo; Ying Shi; Jian Guo; Rui Guo; Jun Xie; Bao Li Journal: Am J Transl Res Date: 2016-09-15 Impact factor: 4.060
Authors: Kai-Uwe Jarr; Sabine Eschricht; Linda C Burkly; Michael Preusch; Hugo A Katus; Norbert Frey; Emmanuel Chorianopoulos Journal: Mediators Inflamm Date: 2014-02-20 Impact factor: 4.711